ライフサイエンスコーパス: prognostic factor

1 te within TCe and IF was an independent poor prognostic factor.

2 tio was found to be an independent favorable prognostic factor.

3 h C-peptide >252 pmol/L emerging as the best prognostic factor.

4 ogic features and was an independent adverse prognostic factor.

5 8:CD4 ratio was identified as an independent prognostic factor.

6 The R status was not an independent prognostic factor.

7 of MBC patients and may represent a negative prognostic factor.

8 ivation of the COX-2 pathway, was a negative prognostic factor.

9 LC]) >180 mg/L as an overall strong negative prognostic factor.

10 s and tumour distribution were determined as prognostic factors.

11 rations of recurrence risk using established prognostic factors.

12 tage and distant metastasis were independent prognostic factors.

13 ies reporting long-term sequelae, HRQoL, and prognostic factors.

14 gender and age at diagnosis, two other known prognostic factors.

15 kines and tumor EBV status are the strongest prognostic factors.

16 level of methodological rigour in studies of prognostic factors.

17 TMB, and BRAF and RAS mutations are negative prognostic factors.

18 l (OS) was evaluated and compared with known prognostic factors.

19 prognostic values to commonly used clinical prognostic factors.

20 d models were built by combining independent prognostic factors.

21 sible as a result of incomplete data on some prognostic factors.

22 after adjusting for CTC number and clinical prognostic factors.

23 as confirmed after adjustment for individual prognostic factors.

24 l hazards models to adjust for known adverse prognostic factors.

25 Disease (P < 0.0001) scores were independent prognostic factors.

26 res of PDACs with dMMR or MSI might serve as prognostic factors.

27 tional hazards models adjusting for baseline prognostic factors.

28 s was used to match patients for seven known prognostic factors.

29 invasion and lymph node metastasis are poor prognostic factors.

30 which were of advanced age and with adverse prognostic factors.

31 lcohol relapse (P < 0.0001) were independent prognostic factors.

32 was observed after controlling for multiple prognostic factors.

33 by age, response to second-line therapy, and prognostic factors.

34 re lower for BCS but not after adjusting for prognostic factors.

35 of patients in the nivolumab group with poor prognostic factors.

36 d models were built by combining independent prognostic factors.

37 ies reporting long-term sequelae, HRQoL, and prognostic factors.

38 oor overall survival independent of existing prognostic factors.

39 still not clear which are the most important prognostic factors.

40 ed, allowing pooled analysis of 31 potential prognostic factors.

41 as therapeutic targets and might be used as prognostic factors.

42 cer patients and identified several negative prognostic factors.

43 ferase promoter methylation and other strong prognostic factors.

44 5% CI: 1.01-2.63; P = 0.04) were independent prognostic factors.

45 or guarantee-time bias controlling for known prognostic factors.

46 and biologic characteristics were grouped by prognostic factors.

47 es accounting for standard clinicopathologic prognostic factors (10-year biochemical recurrence-free

48 identified the stratification variables and prognostic factors a priori.

49 Established IHD was an important prognostic factor across all HF types.

50 d mortality after adjustment for established prognostic factors (adjusted hazard ratio [HR], 1.55 [95

51 s and tumour distribution were determined as prognostic factors affecting survival rates.

52 We analyzed prognostic factors after neoadjuvant therapy and resecti

53 c survival models were built including known prognostic factors (age, diagnostic delay and site of on

54 assess whether the methodological quality of prognostic factor analyses has changed over time.

55 rdisation and rigour of the methods used for prognostic factor analysis was found compared with the p

56 ric cancer without CEACAM1 is an independent prognostic factor and a risk factor for peritoneal disse

57 on histologic grade, which is the strongest prognostic factor and a routine assessment at biopsy.

58 ntral nervous system involvement is a strong prognostic factor and independent predictor of death.

59 ted the strength of association between each prognostic factor and long-term mortality.

60 ncer and discuss its possible relevance as a prognostic factor and potential therapeutic target in th

61 commentary refers to 'NLRP3 inflammasome as prognostic factor and therapeutic target in primary prog

62 oped a risk stratification system from known prognostic factors and assessed it in the context of ris

63 nts with PEL were then performed to identify prognostic factors and cancer-specific mortality.

64 c regression models, adjusting for important prognostic factors and clustering effects.

65 on patients' OS while accounting for common prognostic factors and demographic characteristics in un

66 ficant prognostic value to existing clinical prognostic factors and may facilitate more individualize

67 Postoperative complications as well as prognostic factors and patterns of relapse during long-t

68 assifier was stronger than existing clinical prognostic factors and remained a strong independent pro

69 d meta-analysis of studies that investigated prognostic factors and survival in patients with progres

70 ed outside of the development of a number of prognostic factors and the CLL International Prognostic

71 ct of these SNPs is independent of classical prognostic factors and there is no heterogeneity between

72 genomic ITH which is a potential independent prognostic factor, and more proportion of PSCs may be be

73 The analysis adjusts for age, clinical prognostic factors, and socioeconomic deprivation; the I

74 Prognostic factors are lacking in neurosarcoidosis (NS),

75 IST presentation and relevance of historical prognostic factors are not well defined.

76 onal studies almost always have bias because prognostic factors are unequally distributed between pat

77 Prognostic factors are well documented for patients with

78 performed incorporating treatment and common prognostic factors as covariates.

79 r time and may reveal the changing impact of prognostic factors as time accrues from the date of surg

80 Irradiation was the only prognostic factor associated with a lower risk for local

81 PRT was an independent prognostic factor associated with improved survival in s

82 MVD is an independent prognostic factor associated with poor DFS in stage II c

83 The analysis of prognostic factors associated with overall survival afte

84 cohol on long-term survival and (2) identify prognostic factors at admission capable of predicting ab

85 e FGFR4-induced signature was an independent prognostic factor beyond subtype and stage.

86 ve outcome, there is limited knowledge about prognostic factors beyond early recanalization.

87 ght rely on severity scores that incorporate prognostic factors, bowel damage assessment and non-inva

88 DGM-CM6 was an independent prognostic factor by multivariate analysis with hazard r

89 Identifying prognostic factors by affordable tools is crucial for gu

90 ards regression analysis to adjust for known prognostic factors, comorbidities, and weight loss.

91 Other highly-ranked genes included proposed prognostic factors (CXCL10, CD4, CD3E) and investigation

92 dition, it is difficult to determine whether prognostic factors directly affect atrophy.

93 B cells are the strongest prognostic factor even in the context of high or low CD8

94 Propensity methods can deal with multiple prognostic factors, even if there are relatively few pat

95 thesia were generated according to the known prognostic factors (extent of resection, methyl-guanine-

96 ught to determine 30-day survival trends and prognostic factors following surgery for acute subdural

97 pDS to NAC was a significant prognostic factor for better recurrence-free survival (P

98 stasis, and their accumulation is a negative prognostic factor for breast cancer.

99 as a first symptom of occult cancer and as a prognostic factor for cancer survival is unknown.

100 mutations were identified as an independent prognostic factor for CCS (hazard ratio [HR], 2.11; P =

101 ted that complement signaling can serve as a prognostic factor for clinical outcome in PAH.Conclusion

102 al density is an independent and significant prognostic factor for curve progression.

103 t low bone mineral density is an independent prognostic factor for curve progression.

104 The presence of TDs is an independent prognostic factor for DFS in patients with stage III CC.

105 of fecal calprotectin can be used only as a prognostic factor for disease recurrence in patients in

106 It was not a significant prognostic factor for EFS (P = .263; HR, 1.312).

107 dvanced pancreatic cancer was an independent prognostic factor for gemcitabine treatment.

108 mm was identified as an optimal cutoff for a prognostic factor for malignant disease in MD or mixed I

109 Age at diagnosis was an independent prognostic factor for metastatic breast cancer patients.

110 MRD, identified as a new prognostic factor for ML-DS patients, can be used for ri

111 Lymphatic metastasis is a high-impact prognostic factor for mortality of breast cancer (BC) pa

112 n adult patients, PF remained an independent prognostic factor for OAS (P = .013; hazard ratio [HR],

113 %ID/L was identified as an independent prognostic factor for OS (hazard ratio, 1.381 per unit),

114 Again, the score was an independent prognostic factor for OS (HR 1.63 [1.14-2.33], p = 0.008

115 revealed that reduced MPV was an independent prognostic factor for overall survival (hazard ratio, 1.

116 evealed that elevated PDW was an independent prognostic factor for overall survival (hazard ratio, 2.

117 rvival analysis, SII remained an independent prognostic factor for overall survival (HR 1.3, 95% CI 1

118 LAT1 expression was found as an independent prognostic factor for overall survival (HR3.46 P = 0.020

119 deep stroma score," which was an independent prognostic factor for overall survival (OS) in a multiva

120 deriving clinical benefit was an independent prognostic factor for overall survival (OS) in a post ho

121 mphoma diagnosis was an independent negative prognostic factor for overall survival and progression-f

122 Response to rituximab induction remained a prognostic factor for overall survival despite treatment

123 atus in these patients is the most important prognostic factor for overall survival.

124 ntified response to rituximab induction as a prognostic factor for overall survival.

125 IDC + DCIS could be a useful prognostic factor for patients with breast cancer, parti

126 histopathological analysis, is an important prognostic factor for patients with pancreatic ductal ad

127 ls in the surgical specimen, is an important prognostic factor for patients with pancreatic ductal ad

128 1 and CHRM3, respectively) represent a worse prognostic factor for PCa progression free survival.

129 TCe and IF was identified as an independent prognostic factor for poor overall, disease-specific, an

130 dissection group, were a strong, independent prognostic factor for recurrence (hazard ratio, 1.78; P=

131 easing age or BMI at baseline was a negative prognostic factor for remission.

132 essive loss of muscle mass might be a useful prognostic factor for septic shock patients.

133 Although PNI is a prognostic factor for survival in many GI cancers, there

134 d with amyloid burden and was an independent prognostic factor for survival in this cohort of patient

135 currence of autoimmune disease is a negative prognostic factor for survival.

136 y sentinel node biopsy (SNB) is an important prognostic factor for T1 melanoma.

137 The lesion focality is a significant prognostic factor for the GA effective radius growth rat

138 Tumor size is a prognostic factor for the majority of solid cancers, but

139 Overall tumor burden may be an important prognostic factor for these patients.

140 ibed that DDIT4 expression is an independent prognostic factor for tripe negative breast cancer resis

141 r-lymph node (LN) metastasis is the dominant prognostic factor for tumor staging and therapeutic deci

142 ate-stage disease (HR 12.23, P = 0.01) was a prognostic factor for worse overall survival in a Cox pr

143 To assess prognostic factors for a second clinical attack and a fi

144 tic review and meta-analysis to identify all prognostic factors for advanced colorectal neoplasia (aC

145 udy of ambulatory DCM patients, we show that prognostic factors for all-cause DCM also predict outcom

146 carcinoma (ICC) in Thailand and identify the prognostic factors for all-causes of death.

147 l thickness and obstruction were significant prognostic factors for cardiovascular death.

148 o CCC pathogenesis and the identification of prognostic factors for CCC progression.

149 Assessment of disease extent and of prognostic factors for complications is paramount to gui

150 Alongside various clinical prognostic factors for diffuse large B-cell lymphoma (DL

151 dy was to establish the disease severity and prognostic factors for disease outcome by analysing freq

152 Secondary outcomes included prognostic factors for ECD loss: tube insertion entry si

153 bMTV and refractory disease were independent prognostic factors for EFS.

154 - and long-term outcome and to determine the prognostic factors for end-stage kidney disease patients

155 as used to assess outcomes and determine the prognostic factors for initiating stepdown.

156 h cancer and COVID-19 and identify potential prognostic factors for mortality and severe illness.

157 In this paper, we describe the Prognostic Factors for Mortality in Prostate Cancer (Pro

158 0E mutation, and SRC mutation as independent prognostic factors for OS (P = 0.041, P = 0.013, P = 0.0

159 es, and >=2 prior therapies were independent prognostic factors for OS, and (18)F-FDG PET, G3 tumor,

160 atment receipt and (2) determine significant prognostic factors for OS.

161 gery, and duration of epilepsy are important prognostic factors for outcomes of epilepsy surgery.

162 tage, and PDW were identified as independent prognostic factors for overall survival (for PDW, P < 0.

163 Morbidity was significant independent prognostic factors for overall survival (Relative Risk:

164 on, and gene expression of TAM phenotypes as prognostic factors for overall survival in lung cancer.

165 nd vascular involvement were all significant prognostic factors for overall survival.

166 e (P < 0.001) found to be strong independent prognostic factors for pain relief.

167 Identification of prognostic factors for patients with relapsed/refractory

168 imary treatment, which were each independent prognostic factors for PCSM, and age and comorbidity, wh

169 according to treatment strategy and explored prognostic factors for PFS and OS.

170 utated TP53, BIRC3, and SF3B1 as independent prognostic factors for PFS with GClb, whereas for VenG,

171 r, and >=3 liver metastases were independent prognostic factors for PFS.

172 ive treatments available, and the best-known prognostic factors for success are age at diagnosis, age

173 Prognostic factors for surgery included CD diagnosis dur

174 ensus was reached on 27 statements regarding prognostic factors for surgery, complications, chronical

175 Here, we aimed to determine the prognostic factors for survival after gastrostomy placem

176 And two poor prognostic factors for survival are preterm birth at les

177 studies to assess pooled survival rates and prognostic factors for survival in patients with HCM.

178 , determine long-term survival, and identify prognostic factors for survival rates.

179 ultivariate Cox analyses were used to assess prognostic factors for survival.

180 and KIT mutation (exon 11) were significant prognostic factors for the probability of surviving beyo

181 We conducted a systematic review to identify prognostic factors for VTE and bleeding in hospitalized

182 considered studies that identified potential prognostic factors for VTE and bleeding in hospitalized

183 mrEMVI status was again the only significant prognostic factor; furthermore those who showed a good t

184 0-2, and at least two of the three high-risk prognostic factors (Gleason score of >=8, presence of th

185 somatic aberration and its association with prognostic factors have neither been studied in a West A

186 uvant treatment was an independent favorable prognostic factor (HR 0.76, 95% CI 0.58-0.99, P = 0.044)

187 gnostic weight among the well-known clinical prognostic factors (HR: 2.46 and 2.23, respectively, P <

188 For frequently examined prognostic factors, HRs derived by univariate and multiv

189 presence of excessive blasts and other poor prognostic factors, hypomethylating agents are the prefe

190 , adjusting for stratification variables and prognostic factors identified a priori, to compare rates

191 The prognostic factors identified could allow the therapy to

192 sis was found to be a strong and independent prognostic factor in ALS.

193 at expansion has been reported as a negative prognostic factor in amyotrophic lateral sclerosis (ALS)

194 eight loss has been identified as a negative prognostic factor in amyotrophic lateral sclerosis, but

195 se to induction chemotherapy is an important prognostic factor in B-lymphoblastic leukemia (B-ALL).

196 ivity was consistently revealed to be a poor prognostic factor in BM and PB.

197 ortant, but heretofore relatively neglected, prognostic factor in both preclinical and clinical strok

198 nfiltrating lymphocytes (TIL) is a favorable prognostic factor in breast cancer, but what drives immu

199 th exhausted T cells and were an independent prognostic factor in ccRCC.

200 analysis showed that MPV was an independent prognostic factor in CRC (HR = 1.452, 95% CI = 1.118-1.8

201 ESRP1 loss is an adverse prognostic factor in CRC.

202 both BM and PB was an independent, favorable prognostic factor in cumulative incidence of relapse (4-

203 from (18)F-FDG PET/CT baseline studies, is a prognostic factor in diffuse large B-cell lymphoma (DLBC

204 without neoadjuvant therapy and serves as a prognostic factor in EAC.

205 The Ki-67 index is an established prognostic factor in gastrointestinal neuroendocrine tum

206 miR-4516 represents an independent negative prognostic factor in GBM patients and acts as a novel on

207 efulness of plasma EBV load as biomarker and prognostic factor in HIV-positive patients with lymphoma

208 EBV load can be used as a biomarker and as a prognostic factor in HIV-positive patients with lymphoma

209 raventricular hemorrhage (IVH) is a negative prognostic factor in intracerebral hemorrhage (ICH) and

210 d on a sequencing method, are an independent prognostic factor in microsatellite stable stage II CRC.

211 MSI-H is a good prognostic factor in nonmetastatic colon adenocarcinoma.

212 AJCC response score after nCRT is a novel prognostic factor in pathologic stage III rectal cancer

213 ssion of 14q32-encoded miRNAs is a favorable prognostic factor in patients with metastatic cancer.

214 Elevated SII is an independent adverse prognostic factor in patients with resectable gastroesop

215 hed light on the role of IKZF1 aberration as prognostic factor in pediatric ALL and summarize emergin

216 umor was the major inferior disease-specific prognostic factor in physical scores ( P < .01), whereas

217 oms have not been specifically assessed as a prognostic factor in progressive supranuclear palsy (PSP

218 igher risk for metastasis and may serve as a prognostic factor in sarcomas and beyond.

219 oma in ORCH and PC-RPLND specimens was not a prognostic factor in this large retrospective study of p

220 either S100A2 or S100A4 was independent poor prognostic factors in a training cohort of 518 participa

221 ed that ZNF750 and its targets were negative prognostic factors in breast cancer.

222 Genetic parameters are established prognostic factors in chronic lymphocytic leukemia (CLL)

223 erapy of TACE and sorafenib were significant prognostic factors in metastatic HCC.

224 h poor outcome independently of well-defined prognostic factors in neuroblastoma, breast cancer, DLBC

225 depth of tumour infiltration are significant prognostic factors in oesophageal adenocarcinoma (OAC),

226 Most data on mortality and prognostic factors in patients with heart failure come f

227 tumor infiltrating lymphocytes are important prognostic factors in patients with TNBC, although the r

228 levels and lower Gleason scores were better prognostic factors in PCa.

229 l studies are needed to further characterize prognostic factors in pediatric CD and to evaluate the i

230 (LAVI) have been recently proposed as novel prognostic factors in several cardiovascular diseases.

231 Attempts to include additional prognostic factors in staging classifications, in order

232 tudy to date focused on identifying risk and prognostic factors in the aftermath of trauma exposure.

233 Poor prognostic factors in the final model included segmental

234 A better understanding of prognostic factors in ulcerative colitis (UC) could impr

235 fluence DDFI or OS after adjusting for known prognostic factors in young breast cancer patients.

236 Independent prognostic factors include age >=65 years, fever, GCS sc

237 Significant prognostic factors included the original 4 factors used

238 ry tumours and it was highly associated with prognostic factors including high Gleason score, clinica

239 based on the therapeutic question, potential prognostic factors, including age, tumor location, M sta

240 adjusting for lung cancer and cardiovascular prognostic factors, including pre-existing coronary hear

241 Prognostic factors independently associated with an ACO

242 studies; however, the lack of commonality of prognostic factors investigated is a significant limitat

243 management, when controlling for other known prognostic factors, is unclear.

244 host-directed therapy is a lack of reliable prognostic factors needed to guide such therapy.

245 liver metastases (yes vs no), and number of prognostic factors (none vs one, two, or three).

246 the clinical characteristics, outcomes, and prognostic factors of acute coronary syndrome (ACS) even

247 The primary endpoint was to investigate the prognostic factors of acute mesenteric ischemia (AMI) in

248 omography (CT) findings in order to find new prognostic factors of adverse outcome and mortality.

249 l Practice Research Datalink to identify the prognostic factors of all-cause mortality in the severel

250 To identify prognostic factors of and analyze the association of imm

251 describe the characteristics and analyze the prognostic factors of EE in the GAMES cohort.

252 o determine the cumulative incidence and the prognostic factors of ileorectal anastomosis (IRA) failu

253 Prognostic factors of ipsilateral breast tumor recurrenc

254 clinical factors to identify the independent prognostic factors of OS.

255 ations were analyzed to identify independent prognostic factors of overall survival (OS).

256 ment, but not the R status, were independent prognostic factors of overall survival.

257 Knowledge of the prognostic factors of PCa and the bone metastasis patter

258 Prognostic factors of poor clinical outcome from the lit

259 nd 11q deletion are two inversely correlated prognostic factors of poor outcome in neuroblastoma.

260 Although many prognostic factors of primary graft dysfunction after li

261 We investigated the risk and prognostic factors of pure viral sepsis in adult patient

262 urs and of residual tumour after surgery are prognostic factors of recurrence rates and patient survi

263 We performed a retrospective study to assess prognostic factors of survival in all allogeneic SCT rec

264 eplace the balance of both known and unknown prognostic factors offered by randomization.

265 model was applied to separate the effects of prognostic factors on 1) metastasis, and 2) metastasis-f

266 number of ELN (>= or <20) was an independent prognostic factor only in node-negative patients [odds r

267 ions in glycosylation serve as diagnostic or prognostic factors, or as targets for therapy.

268 cancer, most of whom were elderly, had poor prognostic factors, or had serious comorbidities.

269 al mortality, after adjustment on individual prognostic factors (p < 0.001; median adjusted odds rati

270 stered more frequently to patients with poor prognostic factors, postoperative chemotherapy after pre

271 However, prognostic factors predicting poor clinical outcomes of

272 backbone groups on the basis of established prognostic factors: PRETEXT I/II, PRETEXT III, PRETEXT I

273 ta-analysis of obesity (BMI > 30 kg/m2) as a prognostic factor, providing data on 19.3 million indivi

274 , both SNTI and BMM are independent negative prognostic factors regarding DFS and OS, and the occurre

275 This study reanalyses pathological prognostic factors related to IBTR using long-term follo

276 The most common significant prognostic factors reported were physical functioning (1

277 Responses occurred across all PD-L1 and poor prognostic factor subgroups.

278 PET/CT results and SUVs were compared with prognostic factors such as histologic grade (G1, G2, or

279 Despite selection using known prognostic factors survival is varied and morbidity and

280 n the present study had significantly better prognostic factors than the previous SECA-I study.

281 s, and its low expression represented a poor prognostic factor that directly correlated with NK activ

282 out COVID-19 grows, more will be known about prognostic factors that can guide these difficult decisi

283 iomedical literature and synthesize data for prognostic factors that predict long-term mortality in p

284 asingly are used in addition to conventional prognostic factors to guide adjuvant chemotherapy (CT) d

285 Prognostic factors to initiate stepdown included medicat

286 We assessed mortality prognostic factors using random-effects logistic regress

287 The evidence for all prognostic factors was categorized as "weak", "moderate"

288 The number of prognostic factors was significantly associated with the

289 When adjusted for known prognostic factors, we observed a statistically signific

290 Prognostic factors were assessed by univariate analysis

291 Results on most prognostic factors were consistent across methodological

292 INTERPRETATION: Novel prognostic factors were delineated, and the assessment o

293 signed drug and dosing regimen, and baseline prognostic factors were requested from the leaders of th

294 between December 2015 and May 2016, and all prognostic factors were weighted for significance by haz

295 Greater weight loss was a positive prognostic factor, whereas increasing age or BMI at base

296 lobulin G signature was an independent, good prognostic factor, whereas the HER2-enriched signature,

297 level <50 mg/L appeared to be an independent prognostic factor with respect to overall survival (haza

298 A better understanding of prognostic factors within the heterogeneous spectrum of

299 Tumor size was a prognostic factor without significant influence on PFS a

300 inese populations and correlates with poorer prognostic factors: young age-of-onset and lupus nephrit